 Glaucoma is a chronic eye disease that leads to total blindness. Actually it is the second leading cause of blindness and currently 80 million people are suffering, most of them being over 60 years old. The elderly population affected by glaucoma is growing with today's aging population and this threatens to overwhelm eye care capacity everywhere. When glaucoma is detected early, monitored accordingly and treated appropriately, blindness can be significantly delayed. As soon as glaucoma is diagnosed, the patient has been regularly seen by glaucoma specialists and monitored several times a year. One way to monitor and observe the disease is perimetry. You may also know it as visual field testing. Visual field testing however is a test who requires high concentration of the patient for at least eight minutes per eye and this can be very challenging for the patient, especially considering the higher age for usual patient population here. The device is very huge, it's expensive and it also requires a dark room and specialized personnel at the hospital setting. With this current setting we cannot meet the global increasing demand for glaucoma management in the aging population. With ParaVision, our startup, we're really focused in developing and bringing to the market a technology that can radically change the life of patients who suffer from glaucoma. By bringing virtual reality, artificial intelligence and clinical research, we're able to bring a new solution that will really benefit the lives of hundreds of millions of patients who suffer from glaucoma. By combining this technology in this way and pushing to get a product out with this kind of idea, we really see a potential in changing the way things are done in the space of glaucoma and bringing a product forward that is beneficial for society. With the ParaVision team, we have developed a novel portable parametric device that has been clinically validated in two different studies with more than 200 patients. Our unique artificial intelligence algorithm reduces testing time by 70%. The virtual reality headset allows the patients to be tested anywhere and avoids the discomfort of a bulky device in an hospital setting. ParaVision aims to disrupt the current glaucoma care pathway with its mobile faster and less expensive solution. Good glaucoma management and easy-to-use technology can stop preventable vision loss due to delays in testing. We at InSospital believe that ParaVision might be the solution. ParaVision technology will facilitate glaucoma monitoring and treatment in settings beyond hospitals and it has the potential to improve glaucoma care in countries with less access to eye care specialists. Our team is embedded with our clinical partners so technology we develop can address the real-life clinical challenges in early diagnosis and management of glaucoma patients. Following our successful clinical trial here at Burn University Hospital, we plan a much-centered study and pilot trials with partners in Switzerland and beyond to grow the evidence base for our technology and take it one step closer to benefit glaucoma patients.